An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy

被引:1
|
作者
Ma, Xiaoqian [1 ,2 ]
Lin, Nuo [1 ,2 ]
Hu, Ke [1 ,2 ]
Xu, Chao [3 ,4 ]
Yang, Qing [1 ,2 ]
Feng, Yushuo [1 ,2 ]
Liu, Peifei [1 ,2 ]
Ding, Haizhen [1 ,2 ]
Xu, Mengjiao [1 ,2 ]
Shi, Qianqian [1 ,2 ]
Chen, Hongmin [1 ,2 ]
Xue, Fangqin [3 ,4 ]
机构
[1] Xiamen Univ, Ctr Mol Imaging & Translat Med, Sch Publ Hlth, State Key Lab Vaccines Infect Dis,Diang An Biomed, Xiamen, Peoples R China
[2] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Innovat Platform Ind Educ Intergrat Vaccine R, Xiamen, Peoples R China
[3] Fujian Med Univ, Fujian Prov Hosp, Dept Gastrointestinal Surg, Shengli Clin Med Coll, Fuzhou, Fujian, Peoples R China
[4] Fujian Prov Hosp, Clin Med Ctr Digest Dis, Fuzhou, Fujian Province, Peoples R China
基金
中国国家自然科学基金;
关键词
5-Fluorouracil; Colorectal cancer; Chemotherapy; Calcium; Oxidative stress; CALCIUM; CA2+; MITOCHONDRIAL; MECHANISMS;
D O I
10.1016/j.actbio.2024.07.012
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
5-Fluorouracil has demonstrated certain efficiency in patients with colorectal cancer. However, significant side effects of use by injection are common. To address this issue defects, a reengineered 5 '-deoxy-5-fluorocytidine (DFCR) based drug delivery system (POACa) is developed as a prominent tumor-selective nano-activator. Investigations demonstrate that the constructed nano-activator exhibits good biocompatibility and high therapeutic efficiency in mice with subcutaneous and orthotopic SW-480 colorectal tumors, as its activity is strictly dependent on the tumor-associated acid environment and thymidine phosphorylase. These strategies diminish the off-target toxicity and improve the specificity and sensitivity of human colorectal cancer cells to 5-Fu, obtaining potent efficiency by the combination of H2O2 mediated oxidative stress, calcium overload and 5-Fu-induced chemotherapy (the combination index is 0.11). Overall, the engineered nano-activator exhibits a high therapeutic index in vitro and in vivo. Statement of significance In this study, we designed and prepared a pH-responsive polymer to synchronously deliver DFCR (5 '-deoxy-5-fluorocytidine, a prodrug of 5-Fu), Ca2+ and H2O2. The constructed nano-activator was denoted as POACa. (1) To address the problem of premature leakage of cargo by physical embedding, our research modified the inactive prodrug DFCR through chemical bonding. (2) The activation of the prepared nano-activator was strictly dependent on the tumor-associated acid environment and thymidine phosphorylase, providing the drug delivery system with inherent safety. (3) A distinctly low combination index value (0.11) of CaO2 and DFCR indicated that POACa has a prominent tumor suppression effect by tumor calcium overload sensitized chemotherapy and H2O2 mediated cytotoxicity. (c) 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:350 / 360
页数:11
相关论文
共 50 条
  • [1] Acid-activatable oxidative stress-inducing polysaccharide nanoparticles for anticancer therapy
    Yoo, Wooyoung
    Yoo, Donghyuck
    Hong, Eunmi
    Jung, Eunkyeong
    Go, Yebin
    Singh, S. V. Berwin
    Khang, Gilson
    Lee, Dongwon
    JOURNAL OF CONTROLLED RELEASE, 2018, 269 : 235 - 244
  • [2] Doxorubicin-Loaded Metal-Organic Framework Nanoparticles as Acid-Activatable Hydroxyl Radical Nanogenerators for Enhanced Chemo/Chemodynamic Synergistic Therapy
    Li, Honghui
    Zhang, Ying
    Liang, Lingxia
    Song, Jiaxing
    Wei, Zixuan
    Yang, Shuyue
    Ma, Yunong
    Chen, Wei R.
    Lu, Cuixia
    Wen, Liewei
    MATERIALS, 2022, 15 (03)
  • [3] Acid-activatable polymeric curcumin nanoparticles as therapeutic agents for osteoarthritis
    Kang, Changsun
    Jung, Eunkyeong
    Hyeon, Hyejin
    Seon, Semee
    Lee, Dongwon
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020, 23
  • [4] ROS-Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm
    Tamura, Ryo
    Carpenter, Chace I.
    Thomas, Charlotte M.
    Kamyabi, Ghazal
    Hsu, Hsiao-Ting
    Vergnolle, Olivia
    Balderes, Paul
    Grimm, Jan
    ADVANCED THERAPEUTICS, 2024, 7 (12)
  • [5] Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy
    Yang, Chen-Xi
    Xing, Lei
    Chang, Xin
    Zhou, Tian-Jiao
    Bi, Yu-Yang
    Yu, Zhi-Qiang
    Zhang, Zhi-Qi
    Jiang, Hu-Lin
    MOLECULAR PHARMACEUTICS, 2020, 17 (04) : 1300 - 1309
  • [6] Energy Metabolism and Stemness and the Role of Lauric Acid in Reversing 5-Fluorouracil Resistance in Colorectal Cancer Cells
    Fujiwara-Tani, Rina
    Luo, Yi
    Ogata, Ruiko
    Fujii, Kiyomu
    Sasaki, Takamitsu
    Sasaki, Rika
    Nishiguchi, Yukiko
    Mori, Shiori
    Ohmori, Hitoshi
    Kuniyasu, Hiroki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [7] Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies
    Wang, Yuchen
    Xie, Haiyang
    Ying, Kangkang
    Xie, Binbin
    Chen, Xiaona
    Yang, Bing
    Jin, Jiahui
    Wan, Jianqin
    Li, Tongyu
    Han, Weidong
    Fang, Shijiang
    Wang, Hangxiang
    BIOMATERIALS, 2021, 270
  • [8] Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer
    Gerard, B
    Bleiberg, H
    Van Daele, D
    Gil, T
    Hendlisz, A
    Di Leo, A
    Fernez, B
    Brienza, S
    ANTI-CANCER DRUGS, 1998, 9 (04) : 301 - 305
  • [9] Rational design of hypochlorous acid-activatable fluorescent probe for diagnostic imaging and therapeutic evaluation in breast cancer recurrence
    Nie, Gang
    Liang, Wenjie
    Wang, Jun
    Du, Zhaosong
    Xiao, Fengping
    Liu, Maochang
    Chen, Dugang
    Wang, Huiling
    SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2025, 330
  • [10] Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer
    Kim, Se-Lim
    Kim, Seong Hun
    Kieu Thi Thu Trang
    Kim, In Hee
    Lee, Seung-Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Kang, Sang-Beom
    Kim, Sang-Wook
    CANCER LETTERS, 2013, 335 (02) : 479 - 486